# Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

> **NCT00175435** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of British Columbia** · enrollment: 39 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Resiquimod gel
- **BIOLOGICAL:** Resiquimod gel
- **BIOLOGICAL:** Resiquimod gel

## Key facts

- **NCT ID:** NCT00175435
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2010-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175435, "Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00175435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*